Table 1.

Demographical and clinical characteristics of 25 MuSK MG patients

Women, n (%)	15 (60)
Age at onset , y, median (range)	38.5 (2–80)
Follow-up, y, median (range)	5.8 (0.5–33)
Predominant weakness, n (%)
Bulbar	9 (36)
Oculobulbar	12 (48)
Generalized	4 (16)
MGFA* at maximum
II, n (b)	6 (6)
III, n (b)	4 (2)
IV, n (b)	8 (8)
V, n (%)	7 (28)
Immunosuppressive treatment at serum sampling, n (%)	16 (64)

^*Myasthenia Gravis Foundation of America score is a quantitative assessment of muscle weakness.